All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Editor’s Note: The newsletter is taking a much needed rest over the holidays. We’ll be back on January 5th! 🎄 ❄️

THE GOOD
Approvals & Labels

Novo Nordisk files CagriSema (cagrilintide/semaglutide) for FDA approval targeting amylin-GLP-1 pathways in obesity
Protein therapy, metabolic, GLP-1 receptor agonist, obesity, combination therapy, amylin analogue - Read more

THE GOOD
Business Development & Partnerships

Athira Pharma, Sermonix Pharmaceuticals partner on breast cancer drug lasofoxifene, $34.9M equity, $100M milestones
Licensing deal, oncology, small molecule, milestone payments - Read more

GSK, CAMP4 Therapeutics partner on RNA-targeting therapies for neuro, kidney diseases, $440M milestones
Research collaboration, neurological, RNA therapeutics, milestone payments, antisense oligonucleotides - Read more

MRM Health, Oncode Institute, Netherlands Cancer Institute collaborate on microbiome therapeutics for cancer immunotherapy
Research collaboration, oncology, microbiome therapeutics, immunotherapy - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Takeda's zasocitinib (TYK2 inhibitor) succeeds in Ph3 plaque psoriasis trials, regulatory filings planned for 2026
Small molecule, autoimmune, TYK2 inhibitor, plaque psoriasis, zasocitinib - Read more

Eli Lilly's orforglipron (GLP-1 agonist) maintains weight loss in Ph3 ATTAIN-MAINTAIN trial for obesity treatment
Small molecule, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes - Read more

Argenica Therapeutics' ARG-007 shows neuroprotective effects in acute ischaemic stroke Ph2 analysis with AI imaging
Protein therapy, neurological, neuroprotective peptide, acute ischemic stroke, AI biomarkers - Read more

Galapagos reports positive Ph3-enabling results for GLPG3667 TYK2 inhibitor in dermatomyositis, mixed systemic lupus erythematosus outcomes
Small molecule, autoimmune, TYK2 inhibitor, dermatomyositis, systemic lupus erythematosus - Read more

Kalaris Therapeutics reports positive Ph1a data for TH103 targeting VEGF in neovascular age-related macular degeneration
Protein therapy, ophthalmology, fusion protein, neovascular age-related macular degeneration, VEGF inhibitor - Read more

Gain Therapeutics reports positive Ph1b results for GT-02287 targeting glucocerebrosidase pathway in Parkinson's disease
Small molecule, neurological, Parkinson's disease, glucocerebrosidase, allosteric modulator - Read more

THE GOOD
Company Launches

Syremis Therapeutics launches with $165M Series A to develop M1/M4 muscarinic drug rivaling BMS’s Cobenfy for schizophrenia
Neuropsychiatric, small molecule, clinical-stage, schizophrenia - Read more

THE GOOD
Fundraises

Orum Therapeutics raises $100M funding, degrader-antibody conjugates for cancer treatment
Oncology, antibody-drug conjugates, protein degradation, acute myeloid leukemia, clinical-stage - Read more

Moderna scores $54M CEPI funding for bird flu vaccine development
mRNA technology, infectious disease, vaccine development, clinical-stage - Read more

Atavistik Bio raises $120M Series B, advancing allosteric small molecule therapeutics
Small molecule, rare disease, allosteric inhibitors, platform technology - Read more

Kodiak Sciences raises $184M public offering, precommercial retina focused biotechnology company
Retina therapeutics, precommercial, biotechnology - Read more

FoRx Therapeutics raises $50M Series A for precision anti-cancer therapeutics development
Cancer, small molecule, clinical-stage, DNA damage response - Read more

KIFFIK Biomedical closes Series A for molecular diagnostics platform expansion
Molecular diagnostics, platform technology, oncology, precision medicine, real-time monitoring - Read more

Insilico Medicine aims for $292M IPO on the Hong Kong Stock Exchange, AI-powered drug discovery and development platform
AI/ML platform, drug discovery, small molecule, platform technology - Read more

THE GOOD
Investments

Novartis builds largest global R&D hub outside Switzerland in India with 9,000 employees
Small molecule, cardiovascular, strategic, operational - Read more

THE GOOD
Regulatory

FDA considers priority vouchers for Merck & Co.'s cholesterol drug and cancer ADC with blockbuster potential
Antibody-drug conjugate, oncology, small molecule, cardiovascular, regulatory, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Daiichi Sankyo, Merck & Co. pause Ph3 trial of ifinatamab deruxtecan for small-cell lung cancer following patient deaths
Antibody-drug conjugate, cancer, small cell lung cancer, B7-H3 target, interstitial lung disease - Read more

Verge Genomics terminates VRG50635 Ph1 trial for amyotrophic lateral sclerosis after failing efficacy analysis
Small molecule, neurological, amyotrophic lateral sclerosis, AI drug discovery, clinical trial failure - Read more

Insmed's Brinsupri (brensocatib) fails Ph2b trial for chronic rhinosinusitis without nasal polyps indication
Small molecule, respiratory disease, brensocatib, bronchiectasis, chronic rhinosinusitis - Read more

THE BAD
Layoffs

Empower Pharmacy cuts 285 jobs, shuts New Jersey facility amid quality allegations and legal challenges
GLP-1 agonist, metabolic disease, operational, cost reduction - Read more [Paywall]

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here